{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-060221","form_type":"8-K","ticker":"MIST","cik":"0001408443","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.285525+00:00","generated_at":"2026-06-02T02:03:39.673936+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Milestone restarts PSVT NDA for etripamil; cash of $89.5M funds into 2026","bullets":["NDA for etripamil in PSVT resubmitted after FDA Type A meeting; standard review expected, potential approval in H1 2025.","Cash, equivalents and short-term investments of $89.5M as of March 31, 2024, expected to fund operations into 2026.","No revenue in Q1 2024 vs $1.0M in Q1 2023; net loss of $10.4M improved from $15.0M a year ago.","R&D expense fell to $3.6M from $10.3M due to completion of Phase 3 PSVT studies.","March 2024 public offering of common shares and pre-funded warrants raised net proceeds of ~$32.2M for development and commercialization."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-060221","json":"https://secwatch.observer/filing/0001104659-24-060221.json","markdown":"https://secwatch.observer/filing/0001104659-24-060221.md","text":"https://secwatch.observer/filing/0001104659-24-060221.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1408443/000110465924060221/0001104659-24-060221-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1408443/000110465924060221/tm2414191d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:03:39.673936+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2f7168a1e4792798c836f60067eb8f41eb722d0a","claim":"Milestone Pharmaceuticals Inc. reported first quarter ended March 31, 2024 results: revenue no revenue, net income net loss was $10.4 million.","evidence_excerpt":"Milestone Pharmaceuticals Inc. (the \"Company\") issued a press release announcing its financial results for the first quarter ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465924060221/0001104659-24-060221-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"no revenue"},{"label":"Net income","value":"net loss was $10.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}